EDITORIALI - Editorials
Volume:
Biochimica Clinica 2020; 44(1) 000-012
Pubblicato on-line:
Marzo 31, 2020
DOI:
10.19186/BC_2020.011
La diagnostica di laboratorio della malattia di von Willebrand è indispensabile per la corretta gestione terapeutica del paziente
AUTORI
BIBLIOGRAFIA
1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood
1987;69:454-9.
2. Mannucci PM. Treatment of von Willebrand’s Disease. N Engl J Med 2004;351:683-94.
3. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-9.
4. Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi): the first recombinant product licensed for the treatment of von
Willebrand disease. Expert Rev Hematol 2016;9:825-30.
5. Favaloro EJ, Franchini M, Lippi G. Biological therapies for von Willebrand disease. Expert Opin Biol Ther 2012;12:551-64.
6. Mannucci PM, Franchini M, Castaman G, et al, on behalf of the Italian Association of Hemophilia Centers. Evidence based
recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009;7:117-26.
7. Favaloro EJ, Lillicrap D, Lazzari MA, et al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia
2004;10(Suppl. 4):164-8.
8. Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clin Lab 2005;51:367-72.
9. Mannucci PM, Franchini M. Von Willebrand’s Disease. N Engl J Med 2017;376:701.
10. Morelli B, Stufano F, per il Gruppo di Studio SIBioC Emostasi. Raccomandazioni per la diagnosi di laboratorio della malattia
di von Willenrand. Biochim Clin 2020;44:73-85.
